Gemcitabine plus carboplatin in platinum-sensitive recurrent ovarian carcinoma

Expert Review of Anticancer Therapy
M Faruk KoseGökhan Tulunay

Abstract

Although the general intent of treatment for patients with recurrent ovarian cancer is palliative, and cure does not seem to be a realistic objective in this setting, median overall survival is greater than 12 months in platinum-sensitive recurrent ovarian cancer. Patients with ovarian cancer can now expect that the time from first relapse of their disease to death will be longer than the period from diagnosis to that first relapse. There is current evidence from prospective randomized trials that carboplatin combined with either paclitaxel or gemcitabine confers a progression-free survival advantage over platinum monotherapy for patients with platinum-sensitive relapsed ovarian cancer. Since the efficacy of paclitaxel/platinum and gemcitabine/carboplatin regimens appears to be comparable based on similar progression-free survival (both combinations confer a 3-month advantage), toxicity profiles should be taken into account when deciding on the combination to be used. The gemcitabine/carboplatin combination should be preferred in patients with underlying peripheral neuropathy. Since alopecia associated with paclitaxel can diminish the overall quality of life, the gemcitabine plus carboplatin combination may be preferable for pa...Continue Reading

References

Apr 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M Markman, W Hoskins
Mar 11, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M MarkmanJ L Lewis
Dec 24, 1997·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E A EisenhauerM van Glabbeke
Sep 14, 1999·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·A du BoisH G Meerpohl
Mar 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert F Ozols
Mar 6, 2003·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Maurie Markman
Jul 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert F OzolsUNKNOWN Gynecologic Oncology Group
Sep 4, 2003·Journal of the National Cancer Institute·Andreas du BoisUNKNOWN Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group
Dec 6, 2003·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·A González-Martín, UNKNOWN Geico Group
Mar 10, 2004·Onkologie·J Pfisterer
Jul 31, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Maurie MarkmanJerome Belinson
Sep 14, 2004·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·M S ManoM Piccart
Apr 21, 2005·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·R F Ozols
Apr 21, 2005·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·J PfistererUNKNOWN EORTC GCG
Sep 7, 2005·Seminars in Oncology·Robert F Ozols

❮ Previous
Next ❯

Citations

Mar 9, 2007·Cancer Metastasis Reviews·Jing ZhangCarol E Cass
Dec 3, 2011·Nucleosides, Nucleotides & Nucleic Acids·Richard J HoneywellG J Peters
Jul 9, 2011·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Maria LeeEun Ji Nam
Jun 18, 2010·Expert Review of Anticancer Therapy·Josep M Del CampoAna Oaknin
Dec 21, 2010·Journal of Molecular Graphics & Modelling·Uthumporn ArsawangSupot Hannongbua
Jun 16, 2009·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Constantin A DasanuDoru T Alexandrescu
Feb 15, 2018·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Joel PardoRoger M Leblanc

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.